(Q57142532)

https://api.crossref.org/works/10.1517%2F14728210802625671

Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Progestins in breast cancer treatment. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Estrogen as therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Multivariate analysis of prognostic factors in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Prognostic Factors in the Initial Response to Therapy by Patients With Advanced Breast Cancer 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Preclinical investigations with epothilones in breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Clinical studies with epothilones for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Lapatinib in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Evidence-based recommendations for local therapy for soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Predictive markers in breast cancer--the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Gemcitabine in the management of metastatic breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Mitomycin-C and vinblastine in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Platinum compounds in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II study of gemcitabine plus cisplatin in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210802625671